Adamson G D, Kwei L, Edgren R A
Department of Statistics, Syntex Research, Palo Alto, California.
Int J Fertil Menopausal Stud. 1994 Jul-Aug;39(4):215-7.
To compare the efficacy of nafarelin acetate with danazol in the treatment of dysmenorrhea, dyspareunia, and pelvic pain associated with endometriosis.
Prospective, randomized double-blind controlled study. PATIENTS, SETTING, TREATMENTS: Two hundred thirteen patients aged 18 to 48 with laparoscopically confirmed pelvic endometriosis and dysmenorrhea, dyspareunia or pelvic pain were randomly assigned to 6 months of treatment with either nafarelin acetate 800 micrograms per day or 400 micrograms per day, or danazol 800 micrograms per day.
The percentage of patients with dysmenorrhea, dyspareunia or pelvic pain before treatment who still had these symptoms after 6 months of treatment and 6 months following completion of treatment. RESULTS [table: see text]
Nafarelin acetate and danazol both provided significant relief of dysmenorrhea, dyspareunia, and pelvic pain during treatment and for 6 months following treatment in women with endometriosis.
比较醋酸萘法瑞林与达那唑治疗子宫内膜异位症相关痛经、性交困难和盆腔疼痛的疗效。
前瞻性随机双盲对照研究。患者、研究地点、治疗方法：213例年龄在18至48岁之间、经腹腔镜确诊为盆腔子宫内膜异位症且有痛经、性交困难或盆腔疼痛的患者，被随机分配接受为期6个月的治疗，治疗方案为每日服用800微克或400微克醋酸萘法瑞林，或每日服用800微克达那唑。
治疗前有痛经、性交困难或盆腔疼痛的患者，在治疗6个月后及治疗结束后6个月仍有这些症状的患者百分比。结果[表格：见正文]
醋酸萘法瑞林和达那唑在治疗期间及治疗后6个月均能显著缓解子宫内膜异位症女性的痛经、性交困难和盆腔疼痛。
